These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38920090)

  • 41. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.
    Samson M; Devilliers H; Ly KH; Maurier F; Bienvenu B; Terrier B; Charles P; Guillevin L; Besancenot JF; Liozon E; Fauchais AL; Loffroy R; Binquet C; Audia S; Seror R; Mariette X; Bonnotte B
    Eur J Intern Med; 2018 Nov; 57():96-104. PubMed ID: 30054122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study.
    Saito S; Okuyama A; Okada Y; Shibata A; Sakai R; Kurasawa T; Kondo T; Takei H; Amano K
    Rheumatology (Oxford); 2020 Jul; 59(7):1617-1621. PubMed ID: 31665468
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
    Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
    Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tocilizumab, an effective treatment for relapsing giant cell arteritis.
    Oliveira F; Butendieck RR; Ginsburg WW; Parikh K; Abril A
    Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S76-8. PubMed ID: 24854376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?
    Harkins P; Conway R
    Expert Opin Investig Drugs; 2022 Sep; 31(9):921-932. PubMed ID: 34106030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.
    Loricera J; Tofade T; Prieto-Peña D; Romero-Yuste S; de Miguel E; Riveros-Frutos A; Ferraz-Amaro I; Labrador E; Maiz O; Becerra E; Narváez J; Galíndez-Agirregoikoa E; González-Fernández I; Urruticoechea-Arana A; Ramos-Calvo Á; López-Gutiérrez F; Castañeda S; Unizony S; Blanco R
    Arthritis Res Ther; 2024 Jun; 26(1):116. PubMed ID: 38840219
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tocilizumab: a novel therapy for patients with large-vessel vasculitis.
    Salvarani C; Magnani L; Catanoso M; Pipitone N; Versari A; Dardani L; Pulsatelli L; Meliconi R; Boiardi L
    Rheumatology (Oxford); 2012 Jan; 51(1):151-6. PubMed ID: 22075063
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index.
    Berti A; Cornec D; Medina Inojosa JR; Matteson EL; Murad MH
    Semin Arthritis Rheum; 2018 Aug; 48(1):77-82. PubMed ID: 29496228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tocilizumab in the treatment of giant cell arteritis.
    Leuchten N; Aringer M
    Immunotherapy; 2018 Mar; 10(6):465-472. PubMed ID: 29504436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Giant cell arteritis with ocular involvement successfully treated with tocilizumab and very short-course glucocorticoids: A case report.
    Khanna RK; Hage R; Lecler A; Sene T; Vignal-Clermont C; Clavel-Refregiers G
    J Fr Ophtalmol; 2021 Apr; 44(4):481-484. PubMed ID: 33712335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice.
    Calderón-Goercke M; Castañeda S; Aldasoro V; Villa I; Prieto-Peña D; Atienza-Mateo B; Patiño E; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Loricera J; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):112-119. PubMed ID: 32441643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of giant cell arteritis].
    Samson M; Greigert H; Bonnotte B
    Rev Prat; 2023 Apr; 73(4):395-399. PubMed ID: 37289152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis.
    Jogimahanti AV; Kini AT; Irwin LE; Lee AG
    J Neuroophthalmol; 2021 Sep; 41(3):342-350. PubMed ID: 34415267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
    Loricera J; Blanco R; Hernández JL; Castañeda S; Mera A; Pérez-Pampín E; Peiró E; Humbría A; Calvo-Alén J; Aurrecoechea E; Narváez J; Sánchez-Andrade A; Vela P; Díez E; Mata C; Lluch P; Moll C; Hernández Í; Calvo-Río V; Ortiz-Sanjuán F; González-Vela C; Pina T; González-Gay MÁ
    Semin Arthritis Rheum; 2015 Jun; 44(6):717-23. PubMed ID: 25697557
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of giant cell arteritis.
    González-Gay MÁ; Pina T; Prieto-Peña D; Calderon-Goercke M; Gualillo O; Castañeda S
    Biochem Pharmacol; 2019 Jul; 165():230-239. PubMed ID: 31034796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Giant cell arteritis and innovative treatments.
    Costanzo G; Ledda AG; Sambugaro G
    Curr Opin Allergy Clin Immunol; 2023 Aug; 23(4):327-333. PubMed ID: 37357797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Giant Cell Arteritis and Polymyalgia Rheumatica: Treatment Approaches and New Targets.
    Nepal D; Putman M; Unizony S
    Rheum Dis Clin North Am; 2023 Aug; 49(3):505-521. PubMed ID: 37331730
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Treatment of Giant Cell Arteritis in Different Clinical Settings.
    Pfeil A; Oelzner P; Hellmann P
    Front Immunol; 2018; 9():3129. PubMed ID: 30733723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.
    Spiera R; Unizony SH; Bao M; Luder Y; Han J; Pavlov A; Stone JH
    Semin Arthritis Rheum; 2021 Apr; 51(2):469-476. PubMed ID: 33784598
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of steroid-sparing treatments in giant cell arteritis according to the glucocorticoids tapering regimen: A systematic review and meta-analysis.
    Gérard AL; Simon-Tillaux N; Yordanov Y; Cacoub P; Tubach F; Saadoun D; Dechartres A
    Eur J Intern Med; 2021 Jun; 88():96-103. PubMed ID: 33879385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.